Compare Noble Corporation plc (NE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Pfizer Inc — how do they compare? Noble Corporation plc trades at $42.28 (market cap $6.54B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 24.4× Noble Corporation plc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and Pfizer Inc for 158 Days on average.
| NE | PFE | |
|---|---|---|
Market Cap | $6.54B | $159.59B |
Volume | 1,192,391 | 30,937,010 |
Sector | Energy | Health |
52-Week High | $54.37 | $29.02 |
52-Week Low | $26.70 | $23.67 |
Typical Hold Time | 26 Days | 158 Days |
Enterprise Value | $7.97B | $211.09B |
Dividend Yield | 4.88% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $40.97, down 1.16% on the day, with a bearish technical signal driven by moving averages and ADX indicators. The stock's valuation shows a P/E of 43.59 and P/S of 2.14, while recent earnings have been mixed with two misses and one beat in the last three quarters. A long-term drilling contract in Ghana provides operational stability, but investor sentiment is tempered by an ongoing legal investigation noted in recent news.
The outlook for NE is cautious; analyst consensus is a Buy with a $52 price target, implying potential upside, but risks include earnings volatility and legal scrutiny. Positive cash flow and a dividend payment support income investors, yet the bearish technical trend and declining revenue in 2026 warrant close monitoring for any fundamental deterioration.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
